NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing agreement with fellow Chinese firm Xiamen Amoytop Biotech Co., Ltd (SHA: 688278). The agreement, valued at up to RMB 145 million (approximately USD 20.37 million) in upfront and milestone payments, as well as royalties, grants Amoytop the rights to develop, conduct regulatory filings for, and commercialize NucMito’s NM6606 in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan. The drug targets liver fat metabolism and liver fibrosis related diseases. NucMito will maintain all rights to NM6606 outside these territories.
NM6606 is an in-house developed candidate for the treatment of nonalcoholic steatohepatitis (NASH), focusing on the retinoic acid X receptor (RXR α), a distinctive member of the nuclear receptor family. This receptor is involved in the functional regulation of multiple family members and plays a pivotal role in various liver cell types. The drug has demonstrated its ability to effectively ameliorate pathological liver disease characteristics such as steatosis, nodular degeneration, inflammation, and fibrosis, showing potential benefits that could extend into other disease areas.- Flcube.com
